The treatment cannot be worse than the disease is an oft-cited statement representing the
important concept of tolerability; older patients often express concerns about side effects …

Introduction Many treatment regimens have been evaluated in transplant-ineligible (TIE)
patients with newly diagnosed multiple myeloma (NDMM). The objective of this study was to …

Background Elotuzumab plus lenalidomide and dexamethasone has shown improved
progression-free and overall survival versus lenalidomide and dexamethasone in patients …

Haematological malignancies are a heterogeneous group of diseases with diverse
incidence. In Europe, the median age at diagnosis across all disease entities is 69 years …

PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and
dexamethasone (DRd) significantly prolonged progression-free survival in transplant …

Background Despite major therapeutic advances, the rational choice of the most appropriate
first-line regimen in newly diagnosed transplant-ineligible multiple myeloma (TIE-MM) is …

Introduction The prevalence of multiple myeloma (MM) has gradually increased over the last
few decades in India due to growing population, better disease awareness, and improved …

Multiple myeloma is the second most common hematological malignancy in the USA and
Europe. Despite improvements in the 5-year and overall survival rates over the past decade …

达雷妥尤单抗是一种新型人源化抗CD38 单克隆抗体, 可靶向治疗多发性骨髓瘤(multiple
myeloma, MM) 瘤细胞表面的CD38, 直接杀伤肿瘤细胞和通过调节免疫微环境双重作用机制 …

The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients
(NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or …